SALAMANCA, SPAIN and COLOGNE, GERMANY -- (MARKET WIRE) -- 11/16/2005 -- Artemis Pharmaceuticals GmbH (Cologne, Germany) and the Center for Applied Molecular Research Salamanca (CIBASA), a Spanish biotechnology company, today announced the signing of a worldwide marketing agreement. Under the terms of the contract, Artemis and CIBASA will collaborate in marketing CIBASA’s groundbreaking Cancer Stem Cell (CSC) based Oncostem™ technology to pharmaceutical and biotechnology companies for the discovery and development of novel anti-cancer therapies. CIBASA has developed a highly innovative technology platform for the discovery of new drugs for cancer treatment. Oncostem Mouse™ is a collection of novel cancer mouse models that show identical pathology to corresponding human cancers and display responses to known therapeutic agents similar to those observed in cancer patients. These mouse models can be used to test novel cancer agents and validate their ability to treat cancer by affecting cancer stem cells. Further advantages to drug discovery are provided by the Oncostem Cell™ platform in which Cancer Stem Cells from different cancer types can be generated, isolated and characterized. Artemis is the leading company for the generation of tailor made genetically modified mouse models. The company markets its unique ARTEMICE™ technology to its large international network of customers from the pharmaceutical and biotechnology industries. Together the companies will use the Artemis marketing network and technology basis to offer scientific services and opportunities for research collaborations in the field of cancer to future partners and customers. These include drug candidate testing, drug repositioning, target discovery and validation, biomarker identification and the generation of new CSC-based cancer mouse models.
